Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.5052W HIGH $144.00
Volume
25.42 K
Value Traded
132.97 K
Short % Float
0.54%
-9.88%Week
-23.55%1 Month
-21.76%3 Month
+17.85%6 Month
-99.84%5 Year
-99.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
159.97 M
EPS (TTM)
-1.80
P/E Ratio
-
Ent. Value
70.47 M
Total Shares
21.22 M
Float Shares
15.31 M
Insiders
27.85%
Institutions
28.77%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
MSLE Catalyst Timeline
Dated clinical, regulatory and corporate events for Satellos Bioscience Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Satellos Bioscience Inc.
70Total events
14Upcoming
8Tier-1 (high impact)
2025 to 2044Coverage
Upcoming catalysts 2
Event history 41
▲Patent GrantedforazapadinIP / Competition
USPTO issued U.S. Patent No. 12,747,245 covering forazapadin
▲Enrollment CompleteforazapadinTrial
Enrollment completed in BASECAMP Phase 2 trial of forazapadin in DMD
Duchenne muscular dystrophysource ↗
▲IND ClearanceforazapadinIND
FDA clears IND for forazapadin in FSHD
facioscapulohumeral muscular dystrophy (FSHD)source ↗
▲Partnership / LicenseforazapadinCorporate
FSHD Canada Foundation partnership providing up to US$5M non-dilutive financing
facioscapulohumeral muscular dystrophy (FSHD)source ↗
●INN Name AssignedforazapadinCorporate
WHO assigns International Nonproprietary Name 'forazapadin' to SAT-3247
▲Fast Track DesignationSAT-3247Designation
FDA granted Fast Track Designation for SAT-3247 for DMD
Duchenne muscular dystrophy (DMD)source ↗
●Oral PresentationSAT-3247Presentation
Conference call and webcast to review TRAILHEAD data
Duchenne muscular dystrophysource ↗
▲Full ResultsSAT-3247Clinical Data
Six-month interim TRAILHEAD data showing reduced muscle fat fraction, increased effort, stable strength, lower CK, favorable safety
Duchenne muscular dystrophysource ↗
◆Enrollment CompleteSAT-3247Trial
Enrollment completion in BASECAMP expected in Q3 2026
Duchenne muscular dystrophysource ↗
▲Enrollment CompleteforazapadinTrial
Expected completion of enrollment in BASECAMP study
Duchenne muscular dystrophysource ↗
▲Fast Track DesignationSAT-3247Designation
FDA Fast Track Designation for SAT-3247
Duchenne Muscular Dystrophysource ↗
▲Orphan Drug DesignationSAT-3247Designation
FDA Orphan Drug designation for SAT-3247 in DMD
Duchenne muscular dystrophysource ↗
▲Rare Pediatric DiseaseSAT-3247Designation
FDA Rare Pediatric Disease designation for SAT-3247 in DMD
Duchenne muscular dystrophysource ↗
▲Trial InitiationSAT-3247Trial
TRAILHEAD study initiated in the U.S. in adults aged 16-25 years
Duchenne muscular dystrophysource ↗
◆Oral PresentationPresentation
Satellos presentation at Bloom Burton & Co. Healthcare Investor Conference
◆Enrollment UpdateSAT-3247Trial
11 clinical trial sites active in BASECAMP; remaining sites to be activated in Q2 2026
Duchenne muscular dystrophysource ↗
◆Poster PresentationSAT-3247Presentation
Poster presentations at MDA conference
Duchenne muscular dystrophysource ↗
◆Oral PresentationSAT-3247Presentation
Oral presentation of data from completed Phase 1a/b study of SAT-3247 in healthy volunteers and DMD patients
Duchenne muscular dystrophysource ↗
▲Oral PresentationSAT-3247Presentation
Presented initial functional outcomes from 56 days of treatment in TRAILHEAD at MDA 2026
Duchenne muscular dystrophysource ↗
▲Biomarker DataSAT-3247Clinical Data
Reported proteomic data from CL-101 at MDA showing reductions in biomarkers of muscle degeneration
Duchenne muscular dystrophysource ↗
▲Preclinical PoCSAT-3247Preclinical
Presented new preclinical efficacy data in FSHD at MDA
Facioscapulohumeral muscular dystrophysource ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Presentation
◆Oral PresentationSAT-3247Presentation
Virtual KOL event on SAT-3247 in DMD
Duchenne muscular dystrophysource ↗
◆Topline ReadoutSAT-3247Clinical Data
Completed Phase 1a/b clinical trial results in healthy volunteers and adults with DMD
Duchenne muscular dystrophysource ↗
◆Trial InitiationSAT-3247Trial
BASECAMP global Phase 2 pediatric study
Duchenne muscular dystrophysource ↗
◆Oral PresentationPresentation
Fireside chat at Guggenheim Securities Emerging Outlook: Biotech Summit 2026
▲First Patient DosedSAT-3247Trial
First participant dosed in BASECAMP Phase 2 pediatric study
Duchenne muscular dystrophysource ↗
◆Enrollment UpdateSAT-3247Trial
BASECAMP trial actively enrolling, plans to establish 25 sites
Duchenne muscular dystrophysource ↗
▼Equity OfferingCorporate
Closed US$57.2 million public offering including exercise of underwriters' option
▼Equity OfferingCorporate
Closed US$57.2 million equity offering of common shares and pre-funded warrants
▼Equity OfferingCorporate
Pricing of public offering of common shares and pre-funded warrants
◆Management ChangeCorporate
Appointed Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
▲First Patient DosedSAT-3247Trial
Four participants from Phase 1b enrolled in TRAILHEAD and restarted on SAT-3247 in Q4 2025
Duchenne muscular dystrophysource ↗
Past FDA Catalysts and PDUFA Decisions
How MSLE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Forazapadin (SAT-3247) | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$18M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 55%
Micro Cap(rank 362 of 658)
Percentile Rank
Satellos Bioscience Inc. faces pipeline headwinds (35/100), with $187M risk-adjusted pipeline value, led by SAT-3247 in Duchenne Muscular Dystrophy (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SAT-3247 Small moleculeNCT07287189 | Duchenne Muscular Dystrophy | Phase 2 | ACTIVE NOT_RECRUITING | 158 | Feb 28, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every MSLE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SAT-3247 Fast TrackOrphanRare Pediatric | Duchenne muscular dystrophy | Phase 2 | 2026-08-13 | reduction in muscle fat fraction by MRI; increased total effort in all TRAILHEAD participants at month six; favorable safety and tolerability profile; stable strength; improved quality of life reported in six-month follow-up dataRead More | Satellos Reports Second Quarter 2026 Financial Results and Highlights Company ProgressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MSLE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Vivo Capital, LLC | 0.4 % | 4.58 M | 813.67 K |
MSLE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MSLE ranks across every disease it competes in
Competitive Position is a premium feature
See how MSLE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMSLE News
MSLE▼ -5.3%on this news
Satellos Granted Composition of Matter Patent for Forazapadin
Satellos Bioscience Inc. has been granted a composition of matter patent for its lead drug candidate, forazapadin, by the U.S. Patent and Trademark Office. This patent, which protects the drug until September 2044, supports the company's strategy for developing treatments for degenerative muscle diseases. Forazapadin is currently being evaluated in Phase 2 clinical trials for conditions like Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.
Read more →MSLESatellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Satellos Bioscience has completed enrollment for its BASECAMP Phase 2 clinical trial of forazapadin, targeting Duchenne muscular dystrophy in boys aged 7 to 10. The trial aims to evaluate the drug's safety and efficacy, with results expected in early 2027. The company has exceeded its enrollment goals, reflecting strong community engagement and support.
Read more →MSLESatellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Satellos Bioscience has received FDA clearance for its IND application for forazapadin, targeting facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical study in FSHD in Q4 2026, supported by a $5 million partnership with the FSHD Canada Foundation. This collaboration aims to advance the clinical development of forazapadin, which is also being evaluated for Duchenne muscular dystrophy.
Read more →MSLESatellos to Present at the 31st Annual Congress of the World Muscle Society
Satellos Bioscience Inc. will present four scientific posters at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan, from September 29 to October 3, 2026. The presentations will focus on the company's drug candidate Forazapadin, which is being evaluated for its efficacy in treating Duchenne muscular dystrophy. Notable studies include both pediatric and adult trials, showcasing the drug's potential in muscle regeneration.
Read more →MSLE▲ +9.2%on this news
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
Satellos Bioscience announced that its lead drug candidate, SAT-3247, has been assigned the International Nonproprietary Name 'forazapadin'. This designation reflects the program's maturity as the company prepares for regulatory submission and commercialization for Duchenne muscular dystrophy (DMD). Forazapadin is currently undergoing evaluation in two Phase 2 studies and aims to begin another trial for facioscapulohumeral muscular dystrophy (FSHD) by the end of 2026.
Read more →MSLESatellos to Participate in Upcoming Investor Conferences
Satellos Bioscience Inc. announced its participation in two upcoming investor conferences in September 2026. The company will present at the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference. Additionally, Satellos is advancing its drug candidate SAT-3247 for treating degenerative muscle diseases, with ongoing Phase 2 clinical trials.
Read more →MSLESatellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
Satellos Bioscience Inc. reported its Q2 2026 financial results, highlighting progress in its clinical trials for SAT-3247, a treatment for Duchenne muscular dystrophy (DMD). The company noted positive interim data from the TRAILHEAD Phase 2 adult study and is on track to release data from the BASECAMP pediatric trial in Q4 2026. Additionally, Satellos maintains a strong cash position of $61.8 million, supporting its operations through 2027.
Read more →MSLE▲ +9.4%on this news
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Satellos Bioscience Inc. has reported promising six-month interim data from its TRAILHEAD study of SAT-3247, an investigational drug for adults with Duchenne muscular dystrophy (DMD). The study showed a reduction in muscle fat fraction, increased effort in upper limbs, and stable strength among participants. Additionally, the drug demonstrated a favorable safety profile, with no serious adverse events reported. These findings support the continued clinical evaluation of SAT-3247.
Read more →MSLE▲ +11.4%on this news
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Satellos Bioscience has received FDA Fast Track designation for SAT-3247, aimed at treating Duchenne muscular dystrophy (DMD). This designation, along with Orphan Drug and Rare Pediatric Disease designations, underscores the potential of SAT-3247 in addressing unmet medical needs. The drug is currently being evaluated in ongoing Phase 2 clinical trials, with results expected in the second half of 2026.
Read more →MSLE▲ +19.4%on this news· ran to +38% by day 3shared move
Satellos to Present Clinical Program Updates at ICNMD 2026
Satellos Bioscience Inc. will present updates on its SAT-3247 clinical program at the ICNMD 2026 in Florence, Italy. The presentations will include six-month follow-up data from the Phase 1b SAT-3247-CL-101 trial and insights from the ongoing Phase 2 TRAILHEAD trial. SAT-3247 is being developed as a treatment for degenerative muscle diseases, particularly Duchenne muscular dystrophy.
Read more →MSLESatellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos Bioscience Inc. held its Annual Meeting of Shareholders on June 17, 2026, where all management nominees were elected as directors. Shareholder participation reached 55.3%, and the re-appointment of PricewaterhouseCoopers LLP as auditors was approved. The meeting highlighted the company's ongoing commitment to advancing its clinical-stage therapies for degenerative muscle diseases.
Read more →MSLE▲ +5.2%on this news
NOTICE OF MEETING AND MANAGEMENT INFORMATION CIRCULAR RELATING TO THE
Satellos Bioscience Inc. has announced its Annual General Meeting (AGM) set for June 17, 2026, to be held virtually. Shareholders will have the opportunity to receive audited financial statements and vote on board elections. The meeting aims to ensure shareholders can participate remotely, but non-registered attendees will only listen in without the ability to vote. Proxies must be properly registered to ensure voting rights are upheld, following specific instructions outlined in the Management Information Circular.
Read more →MSLESatellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Satellos Bioscience Inc. reported its financial results for Q1 2026, highlighting significant progress in its clinical trials for SAT-3247, a treatment for Duchenne muscular dystrophy (DMD). The company raised $57 million, providing sufficient funding through 2027. The BASECAMP study is actively enrolling participants, while the TRAILHEAD study has commenced in the U.S. for adults aged 16-25. However, the net loss for the quarter increased compared to the previous year.
Read more →MSLESatellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
Satellos Bioscience Inc. will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026. CEO Frank Gleeson will lead the presentation and participate in one-on-one meetings. The conference will highlight Satellos's innovative therapy SAT-3247, aimed at treating degenerative muscle diseases.
Read more →MSLE▼ -10.7%on this news
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Satellos Bioscience Inc. reported its 2025 financial results, highlighting key advancements in its clinical programs, including the initiation of the BASECAMP Phase 2 trial for SAT-3247 in Duchenne muscular dystrophy (DMD). The company also presented promising interim data from the TRAILHEAD trial, showing maintained grip strength improvements. Despite an increase in net loss, Satellos secured $57.2 million in equity financing, extending its cash runway through 2027.
Read more →MSLESatellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Bioscience Inc. will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando, Florida. The presentations will include data from a completed Phase 1a/b study of SAT-3247, a drug aimed at treating Duchenne muscular dystrophy, along with new preclinical data. The conference is scheduled for March 8-11, 2026.
Read more →MSLESatellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
Satellos Bioscience Inc. will host a virtual KOL event on February 24, 2026, featuring Dr. Kevin M. Flanigan. The event will discuss the treatment landscape for Duchenne muscular dystrophy (DMD) and provide insights on SAT-3247, an oral therapy aimed at muscle repair. The session will cover results from previous clinical trials and ongoing studies.
Read more →MSLESatellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
Satellos Bioscience Inc. has announced the dosing of the first participant in its Phase 2 pediatric study, BASECAMP, evaluating the efficacy of SAT-3247 for Duchenne muscular dystrophy. This randomized, double-blind, placebo-controlled trial includes 51 children aged 7 to 9 years and focuses on safety, tolerability, and muscle force impact. The study is considered a potential pivotal trial that could enhance future treatment options for children with Duchenne, as existing therapies are limited. SAT-3247 is a small molecule drug designed to promote muscle regeneration, addressing a significant unmet need in this patient population.
Read more →About Satellos Bioscience Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next MSLE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime